ArticleBiotechnology for biofuels2016
Metabolic engineering of Zymomonas mobilis for 2,3-butanediol production from lignocellulosic biomass sugars.
Article in Biotechnology for biofuels, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 190 citations in OpenAlex.
- S267P mutation of OxyR regulator inSynthetic and systems biotechnology · 2026Article
- A synergistic strategy of metabolic engineering and flocculation recycling for enhanced acetoin production inSynthetic and systems biotechnology · 2026Article
- Seven inducible promoters for Zymomonas mobilis.Microbial cell factories · 2026Article
- Quantifying Membrane Structure and Dynamics during Bioproduct Production inThe journal of physical chemistry. B · 2026Article
- AI-powered high-throughput digital colony picker platform for sorting microbial strains by multi-modal phenotypes.Nature communications · 2025Article
- Rapid monitoring of fermentations: a feasibility study on biological 2,3-butanediol production.Biotechnology for biofuels and bioproducts · 2025Article
- Biofuel production from lignocellulose via thermophile-based consolidated bioprocessing.Engineering microbiology · 2024Review
- Paradigm of engineering recalcitrant non-model microorganism with dominant metabolic pathway as a biorefinery chassis.Nature communications · 2024Article
- Development of a starch-fermenting Zymomonas mobilis strain for bioethanol production.Microbial cell factories · 2024Article
- Separation of 2,3-Butanediol from Fermentation Broth via Cyclic and Simulated Moving Bed Adsorption Over Nano-MFI Zeolites.ACS sustainable chemistry & engineering · 2024Article
- Biosensor-assisted CRISPRi high-throughput screening to identify genetic targets inSynthetic and systems biotechnology · 2024Article
- A new Zymomonas mobilis platform strain for the efficient production of chemicals.Microbial cell factories · 2024Article
- Feedstock/pretreatment screening for bioconversion of sugar and lignin streams via deacetylated disc-refining.Biotechnology for biofuels and bioproducts · 2024Article
- Lipid membrane remodeling and metabolic response during isobutanol and ethanol exposure in Zymomonas mobilis.Biotechnology for biofuels and bioproducts · 2024Article
- Microbial Cell Factories in the Bioeconomy Era: From Discovery to Creation.Biodesign research · 2024Review
- Recovery of 2,3-Butanediol from Fermentation Broth by Zeolitic Imidazolate Frameworks.Industrial & engineering chemistry research · 2023Article
- Development of a counterselectable system for rapid and efficient CRISPR-based genome engineering in Zymomonas mobilis.Microbial cell factories · 2023Article
- Construction and application of high-quality genome-scale metabolic model ofSynthetic and systems biotechnology · 2023Article
- Prospects for engineeringEngineering microbiology · 2023Review
- Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo develop pathways for advanced biofuel production, and to understand the impact of host metabolism and environmental conditions on heterologous pathway engineering for economic advanced biofuels production from biomass, we seek to redirect the carbon flow of the model ethanologen Zymomonas mobilis to produce desirable hydrocarbon intermediate 2,3-butanediol (2,3-BDO). 2,3-BDO is a bulk chemical building block, and can be upgraded in high yields to gasoline, diesel, and jet fuel.
results2,3-BDO biosynthesis pathways from various bacterial species were examined, which include three genes encoding acetolactate synthase, acetolactate decarboxylase, and butanediol dehydrogenase. Bioinformatics analysis was carried out to pinpoint potential bottlenecks for high 2,3-BDO production. Different combinations of 2,3-BDO biosynthesis metabolic pathways using genes from different bacterial species have been constructed. Our results demonstrated that carbon flux can be deviated from ethanol production into 2,3-BDO biosynthesis, and all three heterologous genes are essential to efficiently redirect pyruvate from ethanol production for high 2,3-BDO production in Z. mobilis. The down-selection of best gene combinations up to now enabled Z. mobilis to reach the 2,3-BDO production of more than 10 g/L from glucose and xylose, as well as mixed C6/C5 sugar streams derived from the deacetylation and mechanical refining process.
conclusionsThis study confirms the value of integrating bioinformatics analysis and systems biology data during metabolic engineering endeavors, provides guidance for value-added chemical production in Z. mobilis, and reveals the interactions between host metabolism, oxygen levels, and a heterologous 2,3-BDO biosynthesis pathway. Taken together, this work provides guidance for future metabolic engineering efforts aimed at boosting 2,3-BDO titer anaerobically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.